Allopurinol Therapy in Stage 3 CKD
Introduction to Allopurinol
- The American College of Rheumatology strongly recommends allopurinol as the preferred first-line urate-lowering therapy for all patients, including those with CKD stage ≥3, based on its efficacy, tolerability, safety, and lower cost 1, 2, 3
- Xanthine oxidase inhibitors (allopurinol or febuxostat) are strongly recommended over uricosuric agents like probenecid in patients with moderate-to-severe CKD (stage ≥3) 1, 2, 4
Dosing and Titration
- Begin with ≤100 mg/day, and even lower doses (≤50 mg/day) should be considered in stage 3 CKD patients, with a target serum uric acid level of <6 mg/dL 1, 2, 3
- The lower starting dose mitigates safety issues specific to allopurinol hypersensitivity syndrome 1, 2
Prophylaxis and Management
- Strongly recommend initiating concomitant anti-inflammatory prophylaxis therapy (colchicine, NSAIDs, or prednisone/prednisolone) when starting allopurinol to prevent gout flares 1, 3, 5
- For stage 3 CKD, low-dose colchicine or intra-articular/oral glucocorticoids are preferable to NSAIDs for acute gout flare management 4, 6
Alternative Therapies
- Febuxostat may be considered as an alternative if the patient has documented allopurinol hypersensitivity or severe cutaneous adverse reactions 1, 3
- The American College of Rheumatology conditionally recommends switching from febuxostat to an alternative urate-lowering therapy for patients with a history of cardiovascular disease or new cardiovascular events 3, 7